Basket | Login | Register

 
 
 
 

Clinical Trials Watch

About Alzheimer Europe’s Clinical Trials Watch

The purpose of the Clinical Trials Watch is to provide accessible and up-to-date information on clinical trials (i.e. studies) that are investigating drugs for Alzheimer’s disease and/or dementia. We hope that this information is useful to affected people, their families, carers and anyone with an interest in dementia research. The Clinical Trials Watch is not an exhaustive resource of information. It contains information about clinical trials that are:

  • Currently recruiting participants
  • Conducted at least in one European country
  • In phase III (in these trials the drug / treatment is tested in large groups of people, involving from several hundred to several thousand participants. These trials are conducted to provide stronger evidence of the effectiveness and safety of the new drug / treatment.

From April 2017, we are developing an additional database entitled “ongoing studies but not recruiting participants”. This section includes active studies, participants are receiving an intervention or being examined but new potential participants are not currently being recruited.

Please note that you should not interpret the information provided as a recommendation to use the medicine or to participate in the study.

In the Clinical Trials Watch, you can find information by country, by condition and by study:

  • By country: in this section you can see the countries in which each study is currently recruiting or is planning to recruit participants. This information is reviewed every 3 months.
  • By condition: in this section you can see the condition that each study is looking at: at risk, prodromal, mild, moderate, severe dementia, agitation.
  • By study: please note that an accessible easy read version of each study is available as a pdf. This document has been reviewed by a member of the European Working Group of People with Dementia.

Who is involved in this work?

Alzheimer Europe and its European Working Group of People with Dementia have developed tables containing basic information about each trial included in the Clinical Trials Watch. The contents are based on the information available on public registries, such as the US and EU Clinical Trials Registries. You can find more information about these registries in the following links:

www.ClinicalTrials.gov

www.clinicaltrialsregister.eu

The pharmaceutical companies running the trials have provided feedback on the contents of the tables.

What do the tables contain?

The tables provide information on phase III clinical trials for Alzheimer’s disease and/or dementia. All the clinical trials included are currently recruiting participants. However, it is important to bear in mind that recruitment may not happen in all countries at the same time. Each table contain the following sections:

  1. Study Information
  2. Information about the drug that will be tested in the study
  3. Information about participating in the trial
  4. Who can participate in this study?
  5. Where and when will the study be conducted?
  6. Information for your doctor

How many trials are reported in the CTW?

The CTW reports currently 12 ongoing Phase III clinical trials recruiting participants in Europe. These trials are listened in the table below:

Study

Study sponsor

Name of the drug

Condition

AMARANTH

Eli Lilly

LY3314814

Early Alzheimer's disease

COGNITE

AZTherapies

ALZT-OP1

Evidence of early Alzheimer's disease

CREAD & CREAD2

Hofmann- La Roche

Crenezumab

Prodromal to mild Alzheimer's disease

DAYBREAK-ALZ

Eli Lilly

Lanabecestat

Mild Alzheimer's disease dementia

EARLY

Janssen

JNJ-54861911

Risk for developing Alzheimer's dementia

EMERGE

Biogen

Aducanumab

Early Alzheimer's disease

ENGAGE

Biogen

Aducanumab

Early Alzheimer's disease

GENERATION

Novartis

CAD106 and CNP520

Risk of developing Alzheimer's dementia

MissionAD1 & MissionAD2

Eisai

Elenbecestat

Early Alzheimer's disease

SYMBAD

University of Sussex

Mirtazapine and Carbamazepine

Alzheimer's disease and agitated behaviours

 
 

Last Updated: Tuesday 29 August 2017

 

 
 

Options